Summary
Clozapine is an antipsychotic drug which is unusual in that it has no dopamine receptor-blocking activity. test. All data shown represent the results of at least three experiments which gave similar results.
Results
The effects of dopamine, norepinephrine and clozapine on PRL release by normal cultured rat pituitary cells are shown in £ig. I. All three compounds inhibited PRL release in a dose-dependent manner, the IC~o for dopamine, norepinephrine and clozapine being 30 nM, 400 nM and 6 ~M, respectively.
The inhibition of PRL secretion by dopamine (50-500 riM) was not antagonized by a wide dose-range of 1 nM -1 ~M clozapine, while in the same experiments the dopamine-receptor antagonist haloperldol (5 nM) at least partially neutralized dopamine-medlated inhibition of PRL release (Table I ).
The inhibition of PRL secretion by norepinephrlne (I00 nM-1 ~M) was not affected by a wide dose-range of 1 nM -I~ clozapine. The inhibitory effect of norepinephrine on PRL release was attenuated by haloperidol (5 nM), however, but not by fencolamine (I00 nM -I0 ~d~), prazosine (I00 nM-I0 ~M) or propranolol (i00 nM-10 ~M; data not shown). (7, 23, 24) .
Clozapine is a piperazine derivative of the dibenzodiazepine group, with a stron E antlpsychotic and sedative action (1-5). It has a weak D-I dopamine receptor blocking effect, with special affinity to mesolimbic areas, while it also has strong anti-noradrenergic, anti-histaminergic, and anti-cholinergic Previous studies on the effects of clozapine on PRL release have been conflicting. The drug markedly increased serum PRL levels in rats, when injected intraperitoneally in doses of 5-100 mg/kg (8-10). The PRL-releasing effect of clozapine was only 20-50% of that of chlorpromazine, however. In patients treated with 200-600 mg clozapine per day PRL levels were reported to be moderately increased, especially during the first 4 h after drug administration (II,12), but not thereafter (11, 15, 22) . Chronic therapy of psychotic patients for 2-4 weeks with 600 mg clozapine per day did not increase the PRL levels of the cerebrospinal fluid (12) . So, clozapine is distinctly less potent in its in vivo effects on PRL secretion in both rat and man, but its mechanism of action is unexplained.
Meltzer et al (8) suggested that the increase in serum PRL levels are attributed to clozapine's ability to produce dopamlne blockade at the pituitary level or to inhibit nerve impulse-dopamine release or both. Indeed clozapine was found to displace SH-dihydroergocryptine binding from bovine anterior pituitary membranes (16) and ~H-splroperldol from rat pituitary membranes (17) , but the ICso's of clozapine were about I000 nM in the former and 1320 ± 86 nM in the latter study. (26, 27) . The inactivation of calmodulin by these compounds suppresses not only anterior pituitary hormone secretion which is dependent on calcium ions (27) , but in malignant cells which have been shown often to contain elevated calmodulin levels (28), chronic blockade of its action results in direct antimitotic effects. In these studies trifluoperazine has been most often used: micromolar concentrations of the drug inhibited the growth of human breast and ovarian cancer cells (29, 30) . A similar mechanism of action may explain the effects of high concentrations of clozapin on normal and tumorous PRL secretion.
In conclusion, we showed that clozapine does not interfere at the pituitary level with dopamine-mediated inhibition of PRL release. 
